Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026
Company Deals

JD Healthcare Partners with Jiangsu Yuyue for Medical Device Collaboration

Fineline Cube Nov 22, 2022

JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), has announced a partnership...

Company Drug

Junshi Biosciences’ JunMaiKang Approved by NMPA for Multiple Indications

Fineline Cube Nov 22, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its JunMaiKang, a biosimilar version...

Company Drug

Hengrui Pharmaceuticals Receives FDA ANDA Approval for Gadobutrol Generic

Fineline Cube Nov 22, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving Abbreviated New Drug Application (ANDA) status...

Company Drug

Fosun Pharma’s Bivalent COVID-19 Vaccine Comirnaty Authorized in Hong Kong

Fineline Cube Nov 21, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced obtaining emergency use authorization (EUA) in...

Company Drug

IASO Biotherapeutics Reports Positive Phase I Results for CAR-T Therapy in NMOSD

Fineline Cube Nov 21, 2022

China-based IASO Biotherapeutics has announced the interim results of a Phase I investigator-initiated-trial (ITT) for...

Company Deals Medical Device

ViVest Medical Raises Funds for Wearable Cardioverter Defibrillator Development

Fineline Cube Nov 21, 2022

Suzhou-based device maker ViVest Medical Technology Co., Ltd has reportedly raised “hundreds of millions” of...

Company Drug

Mabwell Receives Approval for Clinical Study of 9MW3011 in Polycythemia Vera

Fineline Cube Nov 21, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving approval to conduct a...

Policy / Regulatory

China’s CDE, HNMPA, and Bo’ao Lecheng Release Real-world Drug Research Measures

Fineline Cube Nov 21, 2022

The Center for Drug Evaluation (CDE), Hainan Medical Products Administration (HNMPA), and Bo’Ao Lecheng Medical...

Company Medical Device

Hotgen Biotech Receives FDA EUA for COVID-19 Antigen Home Test

Fineline Cube Nov 21, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced receiving Emergency Use Authorization (EUA) from...

Company Deals

Wolters Kluwer Partners with China’s NCID to Advance Infectious Disease Diagnosis

Fineline Cube Nov 21, 2022

Holland-based information and software solutions provider Wolters Kluwer has announced a partnership with China’s National...

Policy / Regulatory

Jiangxi Healthcare Security Administration Launches New VBP Tender

Fineline Cube Nov 21, 2022

The Jiangxi Healthcare Security Administration (JHSA) has released a notice of a new volume-based procurement...

Company Deals

Fapon Biotech Partners with CR Pharma to Develop IVD Open Platform Ecosystem

Fineline Cube Nov 21, 2022

China-based biotech Fapon Biotech Inc. has announced a partnership with China Resources Pharmaceutical Commercial Group...

Company Drug

Henlius’ Serplulimab Phase III Study Approved in Spain for LS-SCLC

Fineline Cube Nov 21, 2022

China-based Shanghai Henlius Biotech (HKG: 2696) has announced that its global, multi-center Phase III clinical...

Company Drug

Hainan Poly Pharm Wins Finland Approval for Generic Cytovene-IV

Fineline Cube Nov 21, 2022

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...

Company Drug

Kangtai Biological Completes Phase III Clinical Data Analysis for COVID-19 Vaccine

Fineline Cube Nov 21, 2022

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the completion of the...

Policy / Regulatory

Jiangxi Leads 22-Province Alliance in VBP for Liver Function Test Reagents

Fineline Cube Nov 21, 2022

The provincial drug and medical consumables centralized procurement joint meeting office of Jiangxi has released...

Company Deals

Fapon Biotech Partners with Roche Diagnostics at China International Import Expo

Fineline Cube Nov 18, 2022

China-based biotech Fapon Biotech Inc. has announced a partnership with Swiss major Roche Diagnostics at...

Company Medical Device

China’s Jiangsu Bioda Gains NMPA Approval for Innovative Artificial Blood Vessel

Fineline Cube Nov 18, 2022

The National Medical Products Administration (NMPA) has granted marketing approval to China-based Jiangsu Bioda Life...

Company Drug

Visen Pharmaceuticals Publishes Phase III Data for Lonapegsomatropin in Growth Hormone Deficiency

Fineline Cube Nov 18, 2022

Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...

Company Deals

RongCan Biotech Raises Pre-Series A Funding for mRNA Therapeutics Development

Fineline Cube Nov 18, 2022

China-based nucleic acid-based therapeutics developer RongCan (Shanghai) Biotech Co., Ltd has reportedly raised “tens of...

Posts pagination

1 … 632 633 634 … 700

Recent updates

  • HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases
  • Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals
  • China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio
  • Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy
  • CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Company Medical Device

Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.